← 홈

난소암

353개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 353개
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Phase 1

T cell injection targeting FLT3 chimeric antigen receptor (T cell injection targeting FLT3 chimeric antigen receptor)

FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) peptide vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
ADCBiologicstaleTakedaPhase 2

TAK-853 (TAK-853)

Ovarian Cancer; Solid Tumors · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 44%임상시험 1상태 RECRUITING
CGTBiologicstaleInge Marie SvanePhase 2

TIL infusion (TIL infusion)

Metastatic Ovarian Cancer · Metastatic Ovarian Cancer

#MetastaticOvarianCancer#CGT#Phase2#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 ACTIVE
ADCBiologicstaleTubulis GmbHPhase 2

TUB-040 (TUB-040)

Ovarian Cancer; Non-small Cell Lung Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
ADCBiologicstaleYonsei UniversityPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Trifluridine-tipiracil plus Bevacizumab Alone (Trifluridine-tipiracil plus Bevacizumab Alone)

Refractory Metastatic Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
CGTBiologicstaleCellectis S.A.Phase 1

UCART123v1.2 (UCART123v1.2)

Relapsed/Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
AntibodystaleMersana TherapeuticsPhase 3

Upifitimab rilsodotin (Upifitimab rilsodotin)

High Grade Serous Ovarian Cancer; Fallopian Tube Cancer · High Grade Serous Ovarian Cancer

#HighGradeSerousOvarianCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 1

XmAb808 (XmAb808)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
CGTAAVBiologicstaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

autologous FL-33 CAR T therapy (autologous FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleXiangyang No.1 People's HospitalPhase 2

autologous NK cell (autologous NK cell)

NK Cell; B-cell Lymphoma Recurrent · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 0.667%임상시험 1상태 RECRUITING

17 / 18 페이지

← 이전다음 →